Gut decontamination with norfloxacin and ampicillin enhances insulin sensitivity in mice

Nestle Nutrition Workshop Series: Pediatric Program

Volumn 62, Issue , 2008, Pages 127-137

  Chou, C ^a   Membrez, M ^a   Blancher, F ^a  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; INSULIN; NORFLOXACIN;

ANIMAL; CECUM; CONFERENCE PAPER; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; LIPID METABOLISM; LIVER; METABOLISM; MICROBIOLOGY; MOUSE; MOUSE MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD GLUCOSE; CECUM; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; INSULIN; LIPID METABOLISM; LIVER; MICE; MICE, OBESE; NORFLOXACIN; OBESITY;

ANIMALIA; BACTERIA (MICROORGANISMS); MUS;

EID: 49449085321     PISSN: 16616677     EISSN: 16623878     Source Type: Book Series    
DOI: 10.1159/000146256     Document Type: Conference Paper

References (27)

1. Paster BJ, Boches SK, Galvin JL, et al: Bacterial diversity in human subgingical plaque. J Bacteriol 2001;183:3770-3783.
2. Pei Z, Bini EJ, Yang L, et al: Bacterial biota in the human distal esophagus. Proc Natl Acad Sci USA 2004;101:4250-4255.
3. Bik EM, Eckburg PB, Gill SR, et al: Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci USA 2006;103:732-737.
4. Eckburg PB, Bik EM, Bernstein CN, et al: Diversity of the human intestinal microbial flora. Science 2005;308:1635-1638.
5. Hooper LV, Wong MH, Thelin A, et al: Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001;291:881-884.
6. Stappenbeck TS, Hooper LV, Gordon JI: Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci USA 2002;99:15451-15455.
7. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL: An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005;122:107-118.
8. Hill MJ: Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev 1997;6(suppl 1):S43-S45.
9. Blaut M, Clavel T: Metabolic diversity of the intestinal microbiota: implications for health and disease. J Nutr 2007;137:751S-755S.
10. Bäckhed F, Ding H, Wang T, et al: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101:15718-15723.
11. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI: Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007;104:979-984.
12. Ley RE, Bäckhed F, Turnbaugh P, et al: Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005;102:11070-11075.
13. Turnbaugh PJ, Ley RE, Mahowald MA, et al: An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-1031.
14. Ley RE, Turnbaugh PJ, Klein S, Gordon JI: Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022-1023.
15. Hotamisligil GS, Peraldi P, Budavari A, et al: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271:665-668.
16. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM: Reduced tyrosin kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994;94:1543-1549.
17. Yuan M, Konstantopoulos N, Lee J, et al: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001;293:1673-1677.
18. Hundal RS, Petersen KF, Mayerson AB, et al: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321-1326.
19. Iwamoto Y, Nishimura F, Nakagawa M, et al: The effect of antimicrobial periodontal treatment on circulating tumor necrosis factor-alpha and glycated hemoglobin level in patients with type 2 diabetes. J Periodontol 2001;72:774-778.
20. Cani PD, Amar J, Iglesias MA, et al: Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-1772.
21. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al: Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-241.
22. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-145.
23. Fukata M, Chen A, Klepper A, et al: Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 2006;131:862-877.
24. Magnusson I, Rothman DL, Katz LD, et al: Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 1992;90:1323-1327.
25. Abreu MT, Fukata M, Arditi M: TLR signaling in the gut in health and disease. J Immunol 2005;174:4453-4460.
26. Cario E: Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005;54:1182-1193.
27. Solga SF, Diehl AM: Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003;38:681-687.